Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aripiprazole as protector against COVID-19 mortality

  • Loucera, Carlos
  • Canal-Rivero, Manuel
  • Ruiz‐Veguilla, Miguel
  • Rarmona, Rosario
  • Bostelmann, Gerrit
  • Garrido-Torres, Nathalia
  • Dopazo, Joaquín
  • Crespo-Facorro, Benedicto
The relation of antipsychotics with severe Coronavirus Disease 19 (COVID-19) outcomes is a matter of debate since the beginning of the pandemic. To date, controversial results have been published on this issue. We aimed to prove whether antipsychotics might exert adverse or protective effects against fatal outcomes derived from COVID-19. A population-based retrospective cohort study (January 2020 to November 2020) comprising inpatients (15,968 patients) who were at least 18 years old and had a laboratory-confirmed COVID-19 infection. Two sub-cohorts were delineated, comprising a total of 2536 inpatients: individuals who either had no prescription medication or were prescribed an antipsychotic within the 15 days preceding hospitalization. We conducted survival and odds ratio analyses to assess the association between antipsychotic use and mortality, reporting both unadjusted and covariate-adjusted results. We computed the average treatment effects, using the untreated group as the reference, and the average treatment effect on the treated, focusing solely on the antipsychotic-treated population. Among the eight antipsychotics found to be in use, only aripiprazole showed a significant decrease in the risk of death from COVID-19 [adjusted odds ratio (OR) = 0.86; 95% CI, 0.79-0.93, multiple-testing adjusted p-value < 0.05]. Importantly, these findings were consistent for both covariate-adjusted and unadjusted analyses. Aripiprazole has been shown to have a differentiated beneficial effect in protecting against fatal clinical outcome in COVID-19 infected individuals. We speculate that the differential effect of aripiprazole on controlling immunological pathways and inducible inflammatory enzymes, that are critical in COVID19 illness, may be associated with our findings herein., This work is supported by grants PID2020-117979RB-I00 and TED2021-132346B-I00 from the Spanish Ministry of Science and Innovation, IMPaCT-Data IMP/00019 from the ISCIII, co-funded with European Regional Development Funds (ERDF)., MCR works as Clinical Psychologist at Virgen del Rocío University Hospital (Seville, Spain) via Consejería de Salud y Familias (Junta de Andalucía) 2020 grant which covers his salary (RH-0081-2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ethical and secure evidence generation from regionwide clinical data through a collaborative environment for advancing predictive care

  • Muñoyerro-Muñiz, Dolores
  • Villegas-Portero, Román
  • Oliva, Víctor de la
  • Esteban-Medina, Alberto
  • Fernández Del Valle, Patricia
  • Sánchez, Ana
  • Susin, M. Belén
  • Gutierrez-Álvarez, Isidoro
  • Reboredo, Marta
  • Alejos, Laura
  • Loucera, Carlos
  • Dopazo, Joaquín
This article is part of the Research Topic: Electronic Health Records in Emergency Medicine: From Accountability to Opportunity., Ensuring data protection is a major challenge in clinical research involving sensitive patient information. However, secure processing environments (SPEs) enable the ethical and compliant secondary use of real-world data (RWD) for evidence generation. This study presents a collaborative infrastructure integrating a comprehensive Health Population Database (BPS) with a legal and computational framework to facilitate secure, large-scale clinical studies. The Andalusian Platform for Medical Evidence Generation is an SPE embedded within the Andalusian healthcare network, leveraging RWD from over 15 million patients from the BPS. It supports diverse studies, including treatment efficacy, survival analyses, and predictive modeling, while ensuring alignment with the General Data Protection Regulation (GDPR) and proactively designed to meet forthcoming European Health Data Space (EHDS) requirements. Data are processed within a secure ecosystem, preventing unauthorized access and enabling legally compliant research collaborations. By combining clinical RWD with a robust ethical and legal framework, we present a scalable model for secure, data-driven region-level healthcare innovation. The platform supports cost-effective predictive models, particularly relevant for aging populations, and establishes a blueprint for regional and international adaptation. This approach strengthens the role of healthcare systems in both knowledge generation and sustainable economic growth, ensuring that patient data is leveraged for scientific and societal benefit., The author(s) declare that financial support was received for the research and/or publication of this article. This work has been co-financed by the Spanish Ministry of Science and Innovation with funds from the European Union NextGenerationEU (PRTR-C17.I1) and the Regional Ministry of University, Research and Innovation of the Autonomous Community of Andalusia within the framework of the Biotechnology Plan applied to Health. It is also supported by the Spanish Ministry of Science and Innovation (PID2020-117979RB-I00, PID2023-152380OB-C21, TED2021-132346B-I00), by the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (IMP/00019, PMP24/00024), and by the Consejeria de Salud y Consumo, Junta de Andalucia (IE19_259 FPS)., Peer reviewed